ROCKVILLE, Md.–(BUSINESS WIRE)–Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms and…
Developing and Manufacturing Novel RNAi drug Candidates Using Precision NanoSystems' NxGen™ Platform GAITHERSBURG, MD and VANCOUVER, BC, June 17, 2020 /PRNewswire/…
Emergent BioSolutions (NYSE:EBS) will invest $75M in its Canton, Massachusetts facility, focused on the development and manufacturing of drug substance…
Emergent BioSolutions has unveiled plans to strengthen its contract development and manufacturing (CDMO) capabilities by expanding into viral vector and…